```
=> b reg
FILE 'REGISTRY' ENTERED AT 09:23:49 ON 15 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 AUG 2006  HIGHEST RN 901253-54-1
DICTIONARY FILE UPDATES:  14 AUG 2006  HIGHEST RN 901253-54-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d que sta l23
L21             STR
```




```
VAR G1=O/S
VAR G2=8/13
VAR G3=N/AK/CY
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  20

STEREO ATTRIBUTES: NONE
L23          453 SEA FILE=REGISTRY SSS FUL L21

100.0% PROCESSED    1640 ITERATIONS                    453 ANSWERS
SEARCH TIME: 00.00.01


=> b hcap
FILE 'HCAPLUS' ENTERED AT 09:23:56 ON 15 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
```

FILE COVERS 1907 - 15 Aug 2006 VOL 145 ISS 8
FILE LAST UPDATED: 14 Aug 2006 (20060814/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs fhitstr hitrn l26 tot

L26 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:589549 HCAPLUS
DN 141:140450
TI Preparation of 2-oxopyridin-3-yl thia(di)azoles as Cdk2 and Cdk5 kinase inhibitors for the treatment of cell proliferation-related disorders
IN **Zhong, Wenge; Norman, Mark Henry; Kaller, Matthew; Nguyen, Thomas; Rzasa, Robert Michael; Tegley, Christopher; Wang, Hui-Ling**
PA Amgen Inc., USA
SO PCT Int. Appl., 317 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004060890	A1	20040722	2003WO-US41388	20031222 <--
	WO2004060890	C1	20050818		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US2004147561	A1	20040729	2003US-0736289	20031212 <--
	CA---2509213	AA	20040722	2003CA-2509213	20031222 <--
	AU2003299980	A1	20040729	2003AU-0299980	20031222 <--
	EP---1575947	A1	20050921	2003EP-0800245	20031222 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP2006514059	T2	20060427	2004JP-0565746	20031222 <--
PRAI	2002US-436787P	P	20021227	<--	
	2003US-0736289	A	20031212	<--	
	2003WO-US41388	W	20031222	<--	

OS MARPAT 141:140450
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein A = O or S; Q = NH2 and derivs., NHC(:O)H, alkyl-OH and derivs., (un)substituted monocyclic or bicyclic, etc; W = (un)substituted 1,3-thiazolyl, 1,2,4-thiadiazolyl; R1, R2, R3 =

independently H, halo, aryl, alk(en/yn)yl, perfluoroalkyl, NO2, heterocyclyl, NH2 and derivs., etc.; R1CCR2 or R2CCR3 = 5-10 membered (un)saturated carbocyclic or heterocyclic and derivs.; with provisos; and pharmaceutically acceptable salts thereof] are disclosed as serine/threonine kinase inhibitors for effective treatment of cell proliferation or apoptosis-mediated diseases (no data). The invention encompasses I and pharmaceutically acceptable derivs. thereof, pharmaceutical compns., and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer, and the like (no data). For example, II was prepared by cyclization of bromoacetylpyridinone (III) (preparation given) with 2-(2-thienylsulfonyl)ethanethioamide in EtOH under microwave conditions at 150° for 5 min. II exhibited Cdk2/cyclin and Cdk5/p25 kinase activity with IC50 values < 0.5 μM and inhibited cell proliferation of human PC-3 prostate cells, HCT 116 human colon carcinoma cells, or HT 29 human colon carcinoma cells with IC50 < 1 μM.

IT **727383-80-4P**, 2-Methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid trifluoroacetate
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)

RN 727383-80-4 HCAPLUS

CN 3-Pyridinecarboxylic acid, 1,6-dihydro-2-methyl-6-oxo-5-[2-(4-pyridinyl)-4-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 727383-79-1
CMF C15 H11 N3 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **727383-80-4P**, 2-Methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid trifluoroacetate
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)

IT 727382-46-9P, Ethyl 2-ethyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydropyridine 3-carboxylate 727382-58-3P, Ethyl 2-isopropyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-61-8P, Ethyl 2-isopropyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-78-7P 727383-04-2P, Ethyl 5-[2-(2-chloro-4-pyridinyl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-27-9P, Ethyl 5-[2-[2-(4-Methoxybenzylamino)pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-30-4P, Ethyl 2-methyl-5-[2-(methylamino)-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-52-0P, 2-(Isopropyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylic acid 727383-77-9P, 1,1-Dimethylethyl 2-methyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-89-3P, 5-Hydroxymethyl-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-52-3P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid (2-hydroxyethyl)amide 727384-54-5P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid (2-hydroxypropyl)amide 727384-61-4P, 2-(2-Benzyloxyethyl)-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid ethyl ester 727384-65-8P, 2-(2-Hydroxyethyl)-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid ethyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)

IT 727382-48-1P 727382-49-2P, Ethyl 2-ethyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-50-5P, Ethyl 2-ethyl-6-oxo-5-[2-(benzodioxol-5-yl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-51-6P, Ethyl 6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-(trifluoromethyl)-1,6-dihydro-3-pyridinecarboxylate 727382-53-8P, Ethyl 2-trifluoromethyl-6-oxo-5-[2-(3-chloro-4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-55-0P, Ethyl 6-oxo-5-[2-[(2-pyridylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-(trifluoromethyl)-1,6-dihydro-3-pyridinecarboxylate 727382-56-1P, Ethyl 6-oxo-5-[2-[(2-thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-(trifluoromethyl)-1,6-dihydro-3-pyridinecarboxylate 727382-57-2P, Ethyl 2-trifluoromethyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-60-7P, Ethyl 2-isopropyl-6-oxo-5-[2-[(2-thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-62-9P, Ethyl 2-propyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-65-2P, Ethyl 2-propyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-66-3P, Ethyl 2-propyl-6-oxo-5-[2-[(2-thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-67-4P, Ethyl 6-oxo-2-[(phenylmethoxy)methyl]-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-71-0P, Ethyl 6-oxo-2-[(phenylmethoxy)methyl]-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-72-1P 727382-74-3P, 3-[2-(Pyridin-4-yl)-1,3-thiazol-4-yl]-1,7,8-trihydro-5H-pyrano[4,3-b]pyridin-2-one 727382-76-5P 727382-79-8P , 3-[2-(Pyridin-4-yl)-1,3-thiazol-4-yl]-1,5,6,7,8-pentahydropyridino[3,2-c]pyridin-2-one dihydrochloride 727382-80-1P, Ethyl 2-[[(4-methoxyphenyl)methoxy]methyl]-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-85-6P, Ethyl 2-methyl-6-oxo-5-[2-[(2-thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727382-89-0P, Ethyl 5-[2-[[[(4-fluorophenyl)methyl]sulfonyl]methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727382-90-3P, Ethyl 2-methyl-6-oxo-5-[2-(2-thienyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-

pyridinecarboxylate **727382-92-5P**, Ethyl 2-methyl-6-oxo-5-[2-(phenylthiomethyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-93-6P**, Ethyl 5-[2-(2-ethyl-4-pyridinyl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727382-94-7P**, Ethyl 2-methyl-6-oxo-5-[2-[[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-95-8P**, Ethyl 2-methyl-6-oxo-5-[2-(3-thienyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-96-9P**, Ethyl 5-[2-(2H-benzo[d]-1,3-dioxolan-5-yl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727382-97-0P**, Ethyl 2-methyl-6-oxo-5-(2-phenyl-1,3-thiazol-4-yl)-1,6-dihydro-3-pyridinecarboxylate **727382-98-1P**, Ethyl 2-methyl-6-oxo-5-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-99-2P**, Ethyl 5-[2-(2,6-dichlorophenyl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-00-8P**, Ethyl 2-methyl-5-[2-(2-methyl-1,3-thiazol-4-yl)-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-01-9P**, Ethyl 5-[2-[[(furan-2-ylmethyl)sulfonyl]methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-02-0P**, Ethyl 5-[2-[[(tert-butyl)sulfonyl]methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-03-1P**, Ethyl 2-methyl-6-oxo-5-[2-(3-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-06-4P**, Ethyl 2-methyl-6-oxo-5-[2-(4-methoxyphenyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-07-5P**, Ethyl 5-[2-(3,5-dichloropyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-08-6P**, Ethyl 5-[2-[(methylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-09-7P**, Ethyl 5-[2-[3-[[(4-chlorophenyl)sulfonyl]methyl]-2-thienyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-10-0P**, Ethyl 2-methyl-6-oxo-5-[2-[2-(1-piperidinyl)-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-11-1P**, Ethyl 2-methyl-5-[2-[2-[(2-methylpropyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-12-2P**, Ethyl 2-methyl-6-oxo-5-[2-[2-[(3-pyridinylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-13-3P**, Ethyl 2-methyl-6-oxo-5-[2-[2-[(phenylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-14-4P**, Ethyl 2-methyl-6-oxo-5-[2-[2-[2-oxo-3-(trifluoromethyl)-1(2H)-pyridinyl]ethyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-15-5P**, Ethyl 5-[2-[2-[[2-(diethylamino)ethyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-16-6P**, Ethyl 5-[2-[2-[(fur-2-ylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride **727383-17-7P**, Ethyl 5-[2-[2-[[2-(thien-2-yl)ethyl]amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride **727383-18-8P**, Ethyl 5-[2-[2-(4-fluorobenzylamino)pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride **727383-19-9P**, Ethyl 5-[2-(2-butylaminopyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride **727383-20-2P**, Ethyl 5-[2-[2-[(carbamoylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride **727383-21-3P**, Ethyl 5-[2-[2-[2-(acetylamino)ethylamino]pyridin-4-yl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride **727383-22-4P**, N-[2-[[4-[4-(6-Methyl-2-oxo-1,2-dihydropyridin-3-yl)-1,3-thiazol-2-yl]pyridin-2-yl]amino]ethyl]acetamide **727383-23-5P**, N-(Cyclopropylmethyl)-5-[2-[2-[(cyclopropylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxamide hydrochloride **727383-24-6P**, Ethyl 5-[2-[2-[(cyclopropylmethyl)amino]pyridin-4-yl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride **727383-25-7P**, Ethyl 5-[2-[2-[(Cyclopentylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride **727383-26-8P**, 5-[2-[2-[(4-Methoxybenzyl)amino]pyridin-4-yl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid

N-(4-methoxybenzyl)amide hydrochloride **727383-28-0P**, Ethyl 2-methyl-6-oxo-5-[2-[2-(amino)-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-29-1P** **727383-31-5P**, Ethyl 2-methyl-5-[2-[methyl(phenylsulfonyl)amino]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-32-6P** **727383-33-7P**, Ethyl 2-methyl-5-[2-[methyl(phenylsulfonyl)amino]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride (1/2) **727383-34-8P**, 5-[(Phenylmethyl)oxy]-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone **727383-35-9P**, 6-(Methoxymethyl)-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone **727383-37-1P**, 5-Phenoxy-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone **727383-38-2P**, 5-Phenoxy-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone hydrochloride (1/3) **727383-39-3P**, 6-Methyl-3-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1H-pyridin-2-one **727383-40-6P**, Ethyl 2-(1-methylethyl)-5-[2-(2-methoxy-4-pyridinyl)-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-42-8P**, Ethyl 2-methyl-5-[2-[2-(methoxy)-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-43-9P**, Ethyl 2-methyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-44-0P**, Ethyl 2-methyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-45-1P**, Ethyl 2-methyl-6-oxo-5-[2-[(2-pyridylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-46-2P**, Ethyl 2-methyl-5-[2-[1-methyl-1-(phenylsulfonyl)ethyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-47-3P**, Ethyl 2-cyclopropyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-51-9P**, Ethyl 2-cyclopropyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-53-1P**, 5-Bromo-6-methyl-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone **727383-56-4P**, Ethyl 2-methyl-5-[2-[2-(methylamino)-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-58-6P**, 5-Amino-6-ethyl-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone **727383-65-5P**, N-[2-Ethyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]acetamide **727383-66-6P**, 4-Dimethylamino-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one **727383-68-8P**, 6-Methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-5,6,7,8-tetrahydro-1H-[1,6]naphthyridin-2-one **727383-69-9P**, 2-Methyl-6-oxo-N-(2-pyridinylmethyl)-5-[2-[2-[[(2-pyridinyl)methyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxamide **727383-70-2P**, 6-Methyl-3-[2-[2-[(2-pyridinylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-2(1H)-pyridinone **727383-71-3P**, Ethyl 2-methyl-6-oxo-5-[2-[2-[(2-pyridinylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-72-4P**, Ethyl 2-methyl-6-oxo-5-[2-[2-[[2-(phenyloxy)ethyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-73-5P**, 5-[2-[2-(Ethoxy)-4-pyridinyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid **727383-75-7P**, Ethyl 5-[2-(2-dimethylaminopyridin-4-yl)-1,3-thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-76-8P**, Ethyl 5-[2-(2-methylaminopyridin-4-yl)-1,3-thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride **727383-79-1P**, 2-Methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid **727383-81-5P**, 6-Methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone **727383-82-6P**, 2-(Pyrrolidin-1-yl)ethyl 2-methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylate **727383-84-8P**, 2-(Pyrrolidin-1-yl)ethyl 2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylate **727383-85-9P**, 6-Ethyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one **727383-86-0P**, 6-Isopropyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one **727383-87-1P**, 3-(Diethylamino)propyl 2-ethyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-88-2P**, 3-(Diethylamino)propyl 2-(1-methylethyl)-6-oxo-5-[2-

(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-91-7P**, 5-[(3,6-Dihydro-2H-pyridin-1-yl)methyl]-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one **727383-94-0P**, 6-Ethyl-5-[(piperidin-1-yl)methyl]-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one hydrochloride **727383-96-2P**, 6-Ethyl-5-(4-methylpiperazin-1-ylmethyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one hydrochloride **727383-98-4P**, 6-Ethyl-5-isobutylamino-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one **727384-01-2P**, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridin-3-yl]isobutyramide **727384-03-4P**, 6-Isopropyl-5-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one **727384-06-7P**, 3-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-6-isopropyl-5-methyl-1H-pyridin-2-one **727384-08-9P**, 6-Ethyl-5-propionyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one **727384-10-3P**, 3-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-6-ethyl-5-propionyl-1H-pyridin-2-one **727384-11-4P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-dimethylaminoethyl ester **727384-13-6P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(pyrrolidin-1-yl)ethyl ester **727384-14-7P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(2-oxopyrrolidin-1-yl)ethyl ester **727384-15-8P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-diisopropylaminoethyl ester **727384-16-9P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-diethylaminoethyl ester **727384-17-0P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 1-methylpyrrolidin-3-yl ester **727384-18-1P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 1-ethylpyrrolidin-3-yl ester **727384-19-2P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 1-ethylpiperidin-3-yl ester **727384-20-5P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid piperidin-4-ylmethyl ester **727384-22-7P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(1-methylpyrrolidin-2-yl)ethyl ester **727384-23-8P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 1-methylpiperidin-3-yl ester **727384-24-9P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-dimethylamino-1-methylethyl ester **727384-25-0P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-diethylamino-1-methylethyl ester **727384-26-1P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-[(benzyl)(methyl)amino]ethyl ester **727384-27-2P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 1-methylpiperidin-4-yl ester **727384-28-3P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(piperazin-1-yl)ethyl ester **727384-29-4P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(2-oxopyrrolidin-1-yl)propyl ester **727384-30-7P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid phenethyl ester **727384-32-9P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(thiophen-2-yl)ethyl ester **727384-33-0P**, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 2-diethylaminoethyl ester **727384-36-3P**, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 2-diethylamino-1-methylethyl ester **727384-37-4P**, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 2-diethylaminopropyl ester **727384-38-5P**, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 2-(1-methylpyrrolidin-2-yl)ethyl ester **727384-39-6P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(morpholin-4-yl)ethyl ester

727384-40-9P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(piperidin-1-yl)ethyl ester 727384-41-0P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid methyl ester 727384-42-1P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid methyl ester trifluoroacetate 727384-43-2P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid propyl ester 727384-44-3P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid propyl ester trifluoroacetate 727384-45-4P
, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid butyl ester 727384-46-5P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid butyl ester trifluoroacetate 727384-47-6P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid isobutyl ester 727384-48-7P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid isobutyl ester trifluoroacetate 727384-49-8P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid sec-butyl ester 727384-50-1P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid sec-butyl ester trifluoroacetate 727384-55-6P, 5-(4,5-Dihydrooxazol-2-yl)-6-isopropyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-56-7P, 6-Isopropyl-5-(5-methyl-4,5-dihydrooxazol-2-yl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-57-8P, 5-[[(2-Dimethylaminoethyl)(ethyl)amino]methyl]-6-ethyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-59-0P, 5-[[(2-Diethylaminoethyl)(methyl)amino]methyl]-6-ethyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-66-9P, 6-Oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-2-[2-(pyrrolidin-1-yl)ethyl]-1,6-dihydropyridine-3-carboxylic acid ethyl ester 727384-68-1P, 2-Isopropyl-N-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxamide 727384-69-2P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid amide 727384-70-5P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid isobutylamide 727384-72-7P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid methylamide 727384-73-8P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid (2-isopropylaminoethyl)amide 727384-74-9P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid dimethylamide 727384-75-0P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid N-(pyridin-4-ylmethyl)amide 727384-76-1P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid N-(pyridin-2-ylmethyl)amide 727384-78-3P, 5-(Furan-2-yl)-6-isopropyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-83-0P, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]-2-methylaminoacetamide 727384-84-1P, 2-Dimethylamino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]acetamide 727384-85-2P, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]-3-(piperidin-1-yl)propionamide 727384-86-3P, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]-3-methylbutyramide 727384-87-4P, 2-Amino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]acetamide 727384-88-5P, 2-tert-Butylamino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]acetamide 727384-89-6P, (S)-2-Amino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]-3-methylbutyramide 727384-90-9P, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]-2-(piperidin-1-yl)acetamide 727384-92-1P, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]-4-(piperidin-1-yl)butyramide

727384-93-2P, 5-(1,1-Dioxidoisothiazolidin-2-yl)-6-ethyl-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727384-94-3P, 6-Ethyl-5-(3-methylbutylamino)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-95-4P, Ethyl 5-[2-[2-[(fur-2-ylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 727384-96-5P, Ethyl 5-[2-[2-[[2-(thien-2-yl)ethyl]amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 727384-97-6P, Ethyl 5-[2-(2-butylaminopyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 727384-98-7P, Ethyl 5-[2-[2-[(carbamoylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 727384-99-8P, Ethyl 5-[2-(2-acetylaminoethylamino)pyridin-4-yl-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 727385-00-4P, 5-[2-[2-[(Cyclopropylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(cyclopropylmethyl)amide 727385-02-6P, Ethyl 5-[2-[2-[(cyclopropylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 727385-03-7P, Ethyl 5-[2-[2-[(Cyclopentylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 727385-04-8P, 5-[2-[2-(4-Methoxybenzylamino)pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 4-methoxybenzylamide 727385-06-0P, Ethyl 5-[2-(2-methylaminopyridin-4-yl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylate 727385-07-1P, Ethyl 2-methyl-5-[2-[2-[[2-[(1-methylethyl)amino]ethyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydropyridine-3-carboxylate 727385-08-2P , Ethyl 2-isopropyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate hydrobromide (3/5)
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)

IT 727383-61-1P, Ethyl 2-ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-62-2P, 2-Ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylic acid 727383-63-3P, [2-Ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]carbamic acid tert-butyl ester 727383-64-4P, 5-Amino-6-ethyl-1-(4-methoxybenzyl)-3-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-90-6P, 5-[(Imidazol-1-yl)carbonyl]-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-92-8P, 6-Ethyl-5-hydroxymethyl-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-93-9P, 6-Ethyl-1-(4-methoxybenzyl)-5-[(piperidin-1-yl)methyl]-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-95-1P, 6-Ethyl-1-(4-methoxybenzyl)-5-[(4-methylpiperazin-1-yl)methyl]-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-00-1P, 6-Ethyl-5-isobutylamino-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-02-3P, N-[2-Ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridin-3-yl]isobutyramide 727384-12-5P, 5-[(Imidazol-1-yl)carbonyl]-6-isopropyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-21-6P 727384-34-1P, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydro-3-pyridinecarboxylic acid 727384-35-2P, 3-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-5-[(imidazol-1-yl)carbonyl]-6-isopropyl-1H-pyridin-2-one 727384-58-9P, 5-[[(2-Dimethylaminoethyl)(ethyl)amino]methyl]-6-ethyl-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-60-3P, 5-[[(2-Diethylaminoethyl)(methyl)amino]methyl]-6-ethyl-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)

IT 727383-74-6, 5-[2-(2-Chloropyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 727384-67-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)

L26 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:633706 HCAPLUS
DN 139:180057
TI Preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurological disorders and apoptosis
IN **Norman, Mark**; **Wang, Hui-ling**; **Rzasa, Robert**; **Zhong, Wenge**; Nguyen, Thomas; **Kaller, Matthew**
PA Amgen Inc., USA
SO PCT Int. Appl., 490 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2003066630	A2	20030814	2003WO-US03762	20030207
	WO2003066630	A3	20031218		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US---6822097	B1	20041123	2003US-0360226	20030206
	CA---2475637	AA	20030814	2003CA-2475637	20030207
	AU2003209058	A1	20030902	2003AU-0209058	20030207
	EP---1478645	A2	20041124	2003EP-0707786	20030207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP2005526029	T2	20050902	2003JP-0566003	20030207
PRAI	2002US-355313P	P	20020207		
	2003US-0360226	A1	20030206		
	2003WO-US03762	W	20030207		

OS MARPAT 139:180057
GI



I



II



III



IV

AB The title compds. [I; Ar = II or III; A = O, S, NH; D = CR1, N; E = CR2, N; F = CR3, N; G = CR4, N; J = NR6, S, O, CR1; K = NR6, S, O, CR2; L = NR6, S, O, CR3; Q = OH, (un)substituted NH, aryl, etc.; W = (un)substituted monocyclic (non)aromatic heterocyclic ring; Z = H, (un)substituted NH2, SH, OH, etc.; R1-R4 = H, halo, aryl, etc.; R6 = H, alkyl, a lone pair electrons] and their pharmaceutically acceptable salts, useful for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like, were prepared E.g., a 4-step synthesis of IV (starting from thioisonicotinamide and Me 4-chloroacetoacetate) which showed IC50 of < 1 μM against cdk2/cyclin kinase and against cdk5/p25, was given. A pharmaceutical composition comprising compound I was claimed.

IT **578017-64-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)

RN 578017-64-8 HCAPLUS

CN 5-Quinolinecarboxylic acid, 1,2-dihydro-2-oxo-3-[2-(4-pyridinyl)-4-thiazolyl]-, methyl ester (9CI) (CA INDEX NAME)



IT **578017-64-8P 578017-68-2P 578017-70-6P**
578017-96-6P 578018-16-3P 578018-20-9P
578018-25-4P 578018-29-8P 578018-34-5P
578018-44-7P 578018-57-2P 578018-62-9P
578018-82-3P 578018-85-6P 578018-94-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)

IT **209974-99-2P 578017-57-9P 578017-58-0P**
578017-59-1P 578017-60-4P 578017-61-5P

578017-62-6P 578017-63-7P 578017-65-9P
578017-66-0P 578017-67-1P 578017-69-3P
578017-71-7P 578017-72-8P 578017-73-9P
578017-74-0P 578017-75-1P 578017-76-2P
578017-77-3P 578017-78-4P 578017-79-5P
578017-80-8P 578017-81-9P 578017-82-0P
578017-83-1P 578017-84-2P 578017-85-3P
578017-87-5P 578017-89-7P 578017-90-0P
578017-92-2P 578017-94-4P 578017-95-5P
578017-97-7P 578017-98-8P 578017-99-9P
578018-00-5P 578018-01-6P 578018-02-7P
578018-03-8P 578018-04-9P 578018-05-0P
578018-06-1P 578018-07-2P 578018-08-3P
578018-09-4P 578018-10-7P 578018-11-8P
578018-12-9P 578018-13-0P 578018-14-1P
578018-15-2P 578018-17-4P 578018-18-5P
578018-19-6P 578018-21-0P 578018-22-1P
578018-23-2P 578018-24-3P 578018-26-5P
578018-27-6P 578018-28-7P 578018-30-1P
578018-31-2P 578018-32-3P 578018-33-4P
578018-35-6P 578018-36-7P 578018-37-8P
578018-38-9P 578018-39-0P 578018-40-3P
578018-41-4P 578018-42-5P 578018-43-6P
578018-45-8P 578018-46-9P 578018-47-0P
578018-48-1P 578018-49-2P 578018-50-5P
578018-51-6P 578018-52-7P 578018-53-8P
578018-54-9P 578018-55-0P 578018-56-1P
578018-58-3P 578018-59-4P 578018-60-7P
578018-61-8P 578018-63-0P 578018-64-1P
578018-65-2P 578018-66-3P 578018-67-4P
578018-68-5P 578018-69-6P 578018-76-5P
578018-77-6P 578018-78-7P 578018-79-8P
578018-80-1P 578018-81-2P 578018-83-4P
578018-84-5P 578018-86-7P 578018-87-8P
578018-88-9P 578018-89-0P 578018-90-3P
578018-91-4P 578018-92-5P 578018-93-6P
578018-95-8P 578018-96-9P 578018-97-0P
578018-98-1P 578018-99-2P 578019-00-8P
578019-01-9P 578019-02-0P 578019-03-1P
578019-04-2P 578019-05-3P 578019-06-4P
578019-07-5P 578019-08-6P 578019-09-7P
578019-10-0P 578019-11-1P 578019-12-2P
578019-13-3P 578019-14-4P 578019-15-5P
578019-16-6P 578019-17-7P 578019-18-8P
578019-19-9P 578019-20-2P 578019-21-3P
578019-22-4P 578019-23-5P 578019-24-6P
578019-25-7P 578019-26-8P 578019-27-9P
578019-28-0P 578019-29-1P 578019-30-4P
578019-31-5P 578019-32-6P 578019-33-7P
578019-34-8P 578019-35-9P 578019-36-0P
578019-37-1P 578019-38-2P 578019-39-3P
578019-40-6P 578019-41-7P 578019-42-8P
578019-43-9P 578019-44-0P 578019-45-1P
578019-46-2P 578019-47-3P 578019-48-4P
578019-49-5P 578019-50-8P 578019-51-9P
578019-52-0P 578019-53-1P 578019-54-2P
578019-55-3P 578019-56-4P 578019-57-5P
578019-58-6P 578019-59-7P 578019-60-0P
578020-21-0P 578020-22-1P 578020-24-3P
578020-26-5P 578020-27-6P 578020-28-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)

IT 578020-18-5 578020-20-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)

IT **578020-04-9P 578020-08-3P 578020-09-4P**
578020-11-8P 578020-12-9P 578020-13-0P
578020-14-1P 578020-15-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)

=> d bib abs hitstr retable l28 tot

L28 ANSWER 1 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:610450 HCAPLUS
DN 139:164813
TI Preparation of imidazo[1,2-a]pyridine derivatives as antifungal agents
IN Takemura, Makoto; Takahashi, Hisashi; Kawakami, Katsuhiro; Takeshita, Hiroshi; Kimura, Youichi; Watanabe, Jun; Sugimoto, Yuichi; Kitamura, Akihiro; Nakajima, Ryohei; Kanai, Kazuo; Fujisawa, Tetsunori
PA Daiichi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 309 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2003064422	A1	20030807	2003WO-JP00912	20030130 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA---2474850	AA	20030807	2003CA-2474850	20030130 <--
EP---1479681	A1	20041124	2003EP-0734891	20030130 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US2005113397	A1	20050526	2003US-0502971	20030130 <--
CN---1633434	A	20050629	2003CN-0806794	20030130 <--
NO2004003211	A	20041027	2004NO-0003211	20040728 <--
PRAI 2002JP-0022767	A	20020131 <--		
2003WO-JP00912	W	20030130		
2003WO-JP00913	A	20030130		

OS MARPAT 139:164813
GI



I

AB The title compds. (I), salts thereof, or solvates of either [wherein the

ring A = (un)substituted benzene ring or 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S; R1 = H, halo, each (un)protected NH2, HO, or SH, NO2, cyano, CHO, CO2H, each (un)substituted CONH2, NH2, C1-10 alkyl, C1-10 alkylamino, C1-10 alkoxy, C1-10 alkylthio, C2-6 acyl, C2-7 alkoxycarbonyl, C3-10 cycloalkyl, C3-10 cycloalkylamino, C3-10 cycloalkyloxy, C3-10 cycloalkylthio, C4-10 cycloalkenyl, C4-10 cycloalkenylamino, C4-10 cycloalkenyloxy, C4-10 cycloalkenylthio, C6-10 aryl, C6-10 arylamino, or C6-10 aryloxy, etc.; R2 = H, halo, (un)protected NH2 or OH, NO2, cyano, CO2H, each (un)substituted CONH2, C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, C1-20 alkylamino, C1-20 alkoxy, C2-18 acyl, C2-18 alkoxycarbonyl, C3-10 cycloalkyl, C5-10 cycloalkenyl, C3-10 cycloalkylamino, or C4-16 cycloalkylalkyl, etc.; R3 = H, halo, (un)protected NH2, OH, or SH, NO2, cyano, CHO, CO2H, each (un)substituted CONH2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 alkylthio, C2-5 acyl, or C2-5 alkoxycarbonyl, etc.; R4 = H, halo, (un)protected NH2 or OH, NO2, cyano, CO2H, SO3H, each (un)substituted CONH2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-5 acyl, C2-5 alkoxycarbonyl, C1-6 alkylcarbonyloxy, or C1-6 alkyloxysulfonyl, etc.] are prepared These compds. have a wide spectrum of antifungal activity by a novel mechanism, i.e., specific or selective 1,6-β-glucan synthesis inhibition. Thus, 1-chloro-3-methyl-2-phenylpyrido[1,2-a]benzimidazole-4-carbonitrile, (3S)-dimethylaminopyrrolidine, Et3N, and DMF were heated at 80° for 14 h in a sealed vessel to give 61% 1-[(3S)-dimethylpyrrolidin-1-yl]-3-methyl-2-phenylpyrido[1,2-a]benzimidazole-4-carbonitrile formate (II). II showed min. inhibitory concentration of <0.063, <0.063, and 0.5 μg/mL against Saccharomyces cerevisiae, Candida glabrata, and C. krusei, resp. Pharmaceutical formulations, e.g. a capsule containing 1-[2-(diethylamino)ethylamino]-2-ethyl-3-methylpyrido[1,2-a]benzimidazole-4-carbonitrile, were described.

IT **577776-44-4P 577776-48-8P 577776-51-3P 577777-06-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazo[1,2-a]pyridine derivs. as antifungal agents with specific or selective 1,6-β-glucan)

RN 577776-44-4 HCAPLUS
CN Pyrido[1,2-a]benzimidazole-4-carbonitrile, 1,5-dihydro-3-methyl-2-(2-methyl-4-thiazolyl)-1-oxo- (9CI) (CA INDEX NAME)



RN 577776-48-8 HCAPLUS
CN Pyrido[1,2-a]benzimidazole-4-carbonitrile, 2-(2-ethyl-4-thiazolyl)-1,5-dihydro-3-methyl-1-oxo- (9CI) (CA INDEX NAME)



RN 577776-51-3 HCAPLUS
CN Pyrido[1,2-a]benzimidazole-4-carbonitrile, 1,5-dihydro-3-methyl-1-oxo-2-(2-

phenyl-4-thiazolyl)- (9CI) (CA INDEX NAME)



RN 577777-06-1 HCAPLUS
CN Dipyrido[1,2-a:2',3'-d]imidazole-9-carbonitrile, 1,6-dihydro-8-methyl-7-(2-methyl-4-thiazolyl)-6-oxo- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1992	81	19	Chemico-Biological I	
Anon	2002	124	7972	J Am Chem Soc	
Anon	1989		1895	J Chem Soc Perkin Tr	
Anon	1995		1475	J Chem Soc Perkin Tr	
Anon	1974		647	J Chem Soc, Chem Com	
Daiichi Pharm Co Ltd	2001			WO---0183733 A1	HCAPLUS
Daiichi Pharm Co Ltd	2001			EP---1283261 A1	HCAPLUS
Daiichi Pharm Co Ltd	2001			NO2002005217 A	HCAPLUS

L28 ANSWER 2 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:242331 HCAPLUS
DN 138:271542
TI Preparation of tricyclic pyridin-2-one analogues as GABAA receptor ligands
IN Bourrain, Sylvie; Crawforth, James Michael; Gibson, Karl Richard; Goodacre, Simon Charles; Hallett, David James; Jelley, Richard Alexander; Rowley, Michael; Sternfeld, Francine
PA Merck Sharp & Dohme Limited, UK
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2003024964	A1	20030327	2002WO-GB03693	20020809 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI 2001GB-0019803 A 20010814 <--
OS MARPAT 138:271542
GI



I



II

AB The title selectively substituted fused tricyclic compds. based on a substituted pyridinone moiety I [E = (CH2)n; n = 1-3; one of X, Y and Z = S and the other two of X, Y and Z = N, CH; R1 = H, halo, alkyl, etc.; R2 = (un)substituted (hetero)aryl; provided that, when the X,Y,Z-containing ring is thiazolyl, then R1 is not Me] which are potent and functionally selective ligands for the α2/α3 subunit of the human GABAA receptor and are thereby effective in the treatment of anxiety, were prepared E.g., a 9-step synthesis of II, starting from 3-bromoisonicotinic acid, was given. The exemplified compds. I were found to possess a Ki of ≤ 100 nM for displacement of [3H]-flumazenil from the α2 and/or α3 subunit of the human GABAA receptor.

IT **503301-87-9P 503301-91-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic pyridin-2-one analogs as GABAA receptor ligands)

RN 503301-87-9 HCAPLUS
CN Dipyrido[1,2-a:4',3'-c]azepin-9(5H)-one, 6,7-dihydro-10-(3-methyl-1,2,4-thiadiazol-5-yl)-12-phenyl- (9CI) (CA INDEX NAME)



RN 503301-91-5 HCAPLUS
CN Dipyrido[1,2-a:4',3'-c]azepin-9(5H)-one, 6,7-dihydro-10-(3-methyl-1,2,4-thiadiazol-5-yl)-12-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Hoffmann La Roche	1986			EP---0183994 A	HCAPLUS
James, C	1998			WO---9855480 A	HCAPLUS
Metha	1995	57	2215	LIFE SCIENCES	
Owens, A	1998			WO---9850384 A	HCAPLUS

L28 ANSWER 3 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:173578 HCAPLUS
DN 138:221605
TI Preparation of tricyclic pyridin-2-one analogues as ligands for GABAA receptors
IN Bourrain, Sylvie; Goodacre, Simon Charles; Hallett, David James; Lewis, Richard Thomas; Rowley, Michael; Sternfeld, Francine; Street, Leslie Joseph
PA Merck Sharp & Dohme Limited, UK
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2003018546	A2	20030306	2002WO-GB03703	20020812 <--
WO2003018546	A3	20030717		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI 2001GB-0020345 A 20010821 <--
OS MARPAT 138:221605
GI



I



II

AB The title fused tricyclic compds. I [E = (CH2)n; n = 1-3; Q = the residue of an imidazole or triazole ring; R1, R2 = H, halo, heterocyclyl, etc.; R3 = H, alkyl] which are potent and functionally selective ligands for the α2/α3 subunit of the human GABAA receptor and are thereby effective in the treatment of anxiety and convulsions, were prepared E.g., a 7-step synthesis of II, starting from Et (4-methylthiazol-2-yl)acetate

and 3-aminopropanol, was given. The exemplified compds. I were found to possess a Ki of ≤ 100 nM for displacement of [3H]-flumazenil from the α2 and/or α3 subunit of the human GABAA receptor.

IT 500725-52-0P 500725-59-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic pyridin-2-one analogs as ligands for GABAA receptors)

RN 500725-52-0 HCAPLUS
CN 5H,9H-Imidazo[1,5-a]pyrido[2,1-c][1,4]diazepin-9-one, 6,7-dihydro-10-(2-methyl-4-thiazolyl)-12-phenyl- (9CI) (CA INDEX NAME)



RN 500725-59-7 HCAPLUS
CN 5H,9H-Imidazo[1,5-a]pyrido[2,1-c][1,4]diazepin-9-one, 6,7-dihydro-10-(3-methyl-1,2,4-thiadiazol-5-yl)-12-phenyl- (9CI) (CA INDEX NAME)



L28 ANSWER 4 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:154431 HCAPLUS
DN 138:205041
TI Preparation of tricyclic pyridin-2-one analogues as ligands for GABAA receptors
IN Crawforth, James Michael; Gibson, Karl Richard; Goodacre, Simon Charles; Hallett, David James; Jelley, Richard Alexander; Rowley, Michael; Sternfeld, Francine
PA Merck Sharp & Dohme Limited, UK
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2003016311	A1	20030227	2002WO-GB03705	20020809 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI 2001GB-0019828 A 20010814 <--

OS MARPAT 138:205041
GI



I



II

AB The title selectively substituted fused tricyclic compds. based on a substituted pyridinone moiety [I; E = (CH2)n; n = 1-3; R1 = (un)substituted aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, etc.; R2 = (un)substituted aryl, heteroaryl; R3 = alkyl, hydroxyalkyl, alkenyl, etc.; excluding compds. in which R1 = methylthiazolyl or hydroxymethylthiazolyl] which are potent and functionally selective ligands for the α2/α3 subunit of the human GABAA receptor and are thereby effective in the treatment of anxiety and convulsions, were prepared Thus, reacting 1-{4-[3-(tert-butyldimethylsilyloxy)propyl]pyridin-3-yl}-3-dimethylamino-2-phenylpropenone with 2-(thien-2-yl)acetamide (prepns. given) in the presence of lithium hexamethyldisilazide in THF followed by cyclization of the intermediate by treatment with triphenylphosphine in the presence of DEAD in THF afforded II. The exemplified compds. I showed Ki of ≤100 nM for displacement of [3H]-flumazenil from the α2 and/or α3 subunit of the human GABAA receptor.

IT 500165-79-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tricyclic pyridin-2-one analogs as ligands for GABAA receptors)

RN 500165-79-7 HCAPLUS

CN Dipyrido[1,2-a:3',4'-c]azepin-9(5H)-one, 6,7-dihydro-10-(3-methyl-1,2,4-thiadiazol-5-yl)-12-phenyl- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Albaugh, P	1994			US---5328912 A	HCAPLUS
Denzel, T	1978			US---4072681 A	HCAPLUS
Hoffmann La Roche	1986			EP---0183994 A	HCAPLUS
Horvath	1994			WO---9425461 A	HCAPLUS
Nadin, A	1999	40	4073	TETRAHEDRON LETTERS	HCAPLUS
Neurogen Corp	1994			WO---9415937 A	HCAPLUS
Owens, A	1998			WO---9850384 A	HCAPLUS

L28 ANSWER 5 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:58069 HCAPLUS
DN 138:122639
TI Preparation of thiazols and related compounds as telomerase inhibitors
IN Priepke, Henning; Kauffmann-Hefner, Iris; Hauel, Norbert; Damm, Klaus; Schnapp, Andreas
PA Boehringer Ingelheim Pharma K.-G., Germany
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2003006443	A2	20030123	2002WO-EP07558	20020706 <--
	WO2003006443	A3	20030501		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE--10133665	A1	20030130	2001DE-1033665	20010711 <--
	US2003055263	A1	20030320	2002US-0192456	20020710 <--
PRAI	2001DE-1033665	A	20010711 <--		
	2001US-307449P	P	20010724 <--		

OS MARPAT 138:122639
GI



II



III

AB Title compds. R1-A-B-R2 (I) [R1 = (un)substituted Ph, phenylalkyl, phenylalkenyl, etc.; A = (un)substituted phenylalkyl; B = HN, NHCO, CONH, etc.; R2 = CO2, (un)substituted cycloalkyl, cycloalkenyl, etc.] and their pharmaceutically acceptable salts were prepared For example, coupling of thiazol II and phthalic anhydride afforded claimed benzoic acid III in 30% yield. In telomerase inhibition studies, 3-specific examples of I exhibited IC50 values ranging from < 1 - < 5 μM, e.g., IC50 value of compound III was < 5 μM. Compds. I are claimed useful as telomerase inhibitors.

IT **488816-08-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of thiazols and related compds. as telomerase inhibitors)

RN 488816-08-6 HCAPLUS
CN Benzoic acid, 2-[[[4-(1,2-dihydro-2-oxo-3-quinolinyl)-2-thiazolyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



L28 ANSWER 6 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:237765 HCAPLUS
DN 137:196
TI 3-Heteroaryl-2-pyridones: Benzodiazepine Site Ligands with Functional Selectivity for α2/α3-Subtypes of Human GABAA Receptor-Ion Channels
AU Collins, Ian; Moyes, Christopher; Davey, William B.; Rowley, Michael; Bromidge, Frances A.; Quirk, Kathleen; Atack, John R.; McKernan, Ruth M.; Thompson, Sally-Ann; Wafford, Keith; Dawson, Gerard R.; Pike, Andrew; Sohal, Bindi; Tsou, Nancy N.; Ball, Richard G.; Castro, Jose L.
CS Merck Sharp & Dohme Research Laboratories, The Neuroscience Research Centre, Harlow, CM20 2QR, UK
SO Journal of Medicinal Chemistry (2002), 45(9), 1887-1900
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 137:196
AB A novel series of 3-heteroaryl-5,6-bis(aryl)-1-methyl-2-pyridones were developed with high affinity for the benzodiazepine (BZ) binding site of human γ-aminobutyric acid (GABAA) receptor ion channels, low binding selectivity for α2- and/or α3- over α1-containing GABAA receptor subtypes and high binding selectivity over α5 subtypes. High affinity appeared to be associated with a coplanar conformation of the pyridone and sulfur-containing 3-heteroaryl rings resulting from an attractive S...O intramol. interaction. Functional selectivity (i.e., selective efficacy) for α2 and/or α3 GABAA receptor subtypes over α1 was observed in several of these compds. in electrophysiol. assays. Furthermore, an α3 subtype selective inverse agonist was pro-convulsant and anxiogenic in rodents while an α2/α3 subtype selective partial agonist was anticonvulsant and anxiolytic, supporting the hypothesis that subtype selective BZ site agonists may provide new anxiolytic therapies.
IT **433217-25-5P**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(new class of 2-pyridone GABAA benzodiazepine site ligands with anxiolytic activity)
RN 433217-25-5 HCAPLUS
CN [2,4'-Bipyridin]-6(1H)-one, 3-(4-methoxyphenyl)-1-methyl-5-(3-methyl-1,2,4-thiadiazol-5-yl)- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Atack, J	1999	20	255	Neuropsychopharmacol	HCAPLUS
Bondi, A	1964	68	441	J Phys Chem	HCAPLUS
Broughton, H				WO---9804559	HCAPLUS
Chebib, M	2000	43	1427	J Med Chem	HCAPLUS
Collins, I				US---6200982	HCAPLUS
Collins, I	2000	10	1381	Bioorg Med Chem Lett	HCAPLUS
Collins, I	1999	40	4069	Tetrahedron Lett	HCAPLUS
Creuven, I	1996	26	777	J Chem Crystallogr	HCAPLUS
Dawson, G	2000	295	1051	J Pharmacol Exp Ther	HCAPLUS
Doisy, X	1999	7	921	Bioorg Med Chem	HCAPLUS
Dondoni, A	1984	25	3633	Tetrahedron Lett	HCAPLUS
Hadingham, K	1993	43	970	Mol Pharmacol	HCAPLUS
Hansell, D	1996	C52	136	Acta Crystallogr	HCAPLUS
Huang, Q	1999	16	55	Drug Des Discovery	HCAPLUS
Huang, Q	2000	43	71	J Med Chem	HCAPLUS
Jacobsen, E	1999	42	1123	J Med Chem	HCAPLUS
Jones, G	1984	2	395	Comprehensive Hetero	
Jones, G	1996	5	167	Comprehensive Hetero	HCAPLUS
Knaus, G	1974	39	1192	J Org Chem	HCAPLUS
Korpi, E	1997	29	275	Ann Med	HCAPLUS
Krapcho, A	1973		957	Tetrahedron Lett	HCAPLUS
Krogsgaard-Larsen, P	1997	5	355	Eur J Pharm Sci	
Liang, G	1996	37	6627	Tetrahedron Lett	HCAPLUS
Low, K	2000	290	131	Science	HCAPLUS
Macleod, A	1990	33	2052	J Med Chem	HCAPLUS
Martin, G	1992	57	5907	J Org Chem	HCAPLUS
Martin, I	1999	9	1347	Exp Opin Ther Pat	HCAPLUS
Maurin, J	1999	73	377	Pol J Chem	HCAPLUS
McKernan, R	2000	3	587	Nat Neurosci	HCAPLUS
McKernan, R	1996	19	139	Trends Neurosci	MEDLINE
Mehta, A	1999	29	196	Brain Res Rev	HCAPLUS
Meth-Cohn, O	1984		1173	J Chem Soc, Perkin T	HCAPLUS
Miyaura, N	1981	11	513	Synth Commun	HCAPLUS
Ogura, K	1979	52	2013	Bull Chem Soc Jpn	HCAPLUS
Pellow, S	1986	24	525	Pharmacol, Biochem B	HCAPLUS
Reynolds, D	2001	22	402	Trends Pharmacol Sci	HCAPLUS
Robertson, D	1986	29	635	J Med Chem	HCAPLUS
Rudolph, U	1999	401	796	Nature	HCAPLUS
Rudolph, U	2001	22	188	Trends Pharmacol Sci	HCAPLUS
Sice, J	1954	19	70	J Org Chem	HCAPLUS
Sieghart, W	1999	34	379	Neurochem Int	HCAPLUS
Sieghart, W	2000	21	411	Trends Pharmacol Sci	HCAPLUS
Sigel, E	1997	18	425	Trends Pharmacol Sci	HCAPLUS
Sircar, I	1987	30	1023	J Med Chem	HCAPLUS
Stephenson, F	1995	310	1	Biochem J	HCAPLUS
Tenbrink, R	1994	37	758	J Med Chem	HCAPLUS
Teuber, L	1999	5	317	Curr Pharm Des	HCAPLUS

Tully, W	1991	34	2060	J Med Chem	HCAPLUS
Wafford, K	1993	43	240	Mol Pharmacol	HCAPLUS
Wang, Q	1999	5	125	CNS Drug Rev	HCAPLUS
Watjen, F	1989	32	2282	J Med Chem	HCAPLUS
Whiting, P	1999	34	387	Neurochem Int	HCAPLUS
Wouters, J	1997	C53	892	Acta Crystallogr	HCAPLUS
Yu, S	1999	9	186	Med Chem Res	HCAPLUS
Zhang, W	1995	12	193	Drug Des Discovery	HCAPLUS

L28 ANSWER 7 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:319892 HCAPLUS
DN 134:326520
TI Preparation of naphthyridine derivatives as phosphodiesterase IV inhibitors
IN Iwata, Masahiro; Kawano, Noriyuki; Takuwa, Tomofumi; Shiraki, Ryota; Kobayashi, Miki; Takeuchi, Makoto
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2001030779	A1	20010503	2000WO-JP07433	20001024 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA---2385178	AA	20010503	2000CA-2385178	20001024 <--
	AU2000079560	A5	20010508	2000AU-0079560	20001024 <--
	AU----779081	B2	20050106		
	JP2001192385	A2	20010717	2000JP-0323880	20001024 <--
	JP---3373838	B2	20030204		
	BR2000014981	A	20020716	2000BR-0014981	20001024 <--
	EP---1225173	A1	20020724	2000EP-0970038	20001024 <--
	EP---1225173	B1	20050928		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	RU---2240322	C2	20041120	2002RU-0111005	20001024 <--
	AT----305470	E	20051015	2000AT-0970038	20001024 <--
	US---6740662	B1	20040525	2002US-0111077	20020419 <--
PRAI	1999JP-0302544	A	19991025 <--		
	2000WO-JP07433	W	20001024 <--		

OS MARPAT 134:326520
GI



I

AB The title compds. I [R1 = alkyl, etc.; R2 - R4 = H, alkyl, etc.; R5 = (un)substituted Ph, etc.; R6 = OH, NH2, etc.; X = bond, alkylene, etc.] are prepared I are useful as remedies for respiratory diseases related to

phosphodiesterase IV. Compds. of this invention in vitro showed IC50 values of ≤ 11 nM against phosphodiesterase IV.

IT 337358-29-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of naphthyridine derivs. as phosphodiesterase IV inhibitors)
RN 337358-29-9 HCAPLUS
CN 1,8-Naphthyridin-2(1H)-one, 3-(2-amino-4-thiazolyl)-4-(3-chlorophenyl)-1-ethyl-7-methyl- (9CI) (CA INDEX NAME)



IT 337358-74-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of naphthyridine derivs. as phosphodiesterase IV inhibitors)
RN 337358-74-4 HCAPLUS
CN Acetamide, N-[4-[4-(3-chlorophenyl)-1-ethyl-1,2-dihydro-7-methyl-2-oxo-1,8-naphthyridin-3-yl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Green Cross Corp	1995			JP--07010875 A	HCAPLUS
Matsuura, A	1994	17	498	Biol Pharm Bull	HCAPLUS
Sumitomo Pharmaceutical				JP--09048780 A	HCAPLUS
Sumitomo Pharmaceutical				JP--10212288 A	HCAPLUS
Sumitomo Pharmaceutical				CN---1191536 A	HCAPLUS
Sumitomo Pharmaceutical				CN---1245500 A	HCAPLUS
Sumitomo Pharmaceutical				US---5843957 A	HCAPLUS
Sumitomo Pharmaceutical				US---5843957 A	HCAPLUS
Sumitomo Pharmaceutical				WO---9638445 A1	HCAPLUS
Sumitomo Pharmaceutical				AU---9657808 A1	HCAPLUS
Sumitomo Pharmaceutical				AU---9749688 A1	HCAPLUS
Sumitomo Pharmaceutical				WO---9823615 A1	HCAPLUS
Sumitomo Pharmaceutical				AU---9925473 A1	HCAPLUS
Sumitomo Pharmaceutical	1998			EP----842933 A1	HCAPLUS
Sumitomo Pharmaceutical	1999			EP----947515 A1	HCAPLUS

Sumitomo Pharmaceutical	1999			WO---9943659 A1	HCAPLUS
Yamanouchi Pharmaceutic				CN---1156455 A	HCAPLUS
Yamanouchi Pharmaceutic				US---5817670 A	HCAPLUS
Yamanouchi Pharmaceutic				HU-----76980 A	HCAPLUS
Yamanouchi Pharmaceutic				AU---9532656 A1	HCAPLUS
Yamanouchi Pharmaceutic				WO---9606843 A1	HCAPLUS
Yamanouchi Pharmaceutic	1997			EP----779292 A1	HCAPLUS

L28 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:396846 HCAPLUS
DN 129:115023
TI Ensembles of rings with a coumarin unit. 2. Spectral luminescent properties and spin-orbit coupling in molecules of 3-(2-R-thiazol-4-yl)- and 3-(4-R-thiazol-2-yl)coumarins
AU Doroshenko, A. O.; Posokhov, E. A.; Belokon, Ya. V.; Kovalenko, S. N.; Ivanov, V. V.; Ponomarev, O. A.
CS Kharkov State University, Kharkov, 310077, Ukraine
SO Chemistry of Heterocyclic Compounds (New York) (Translation of Khimiya Geterotsiklicheskikh Soedinenii) (1998), Volume Date 1997, 33(10), 1177-1184
CODEN: CHCCAL; ISSN: 0009-3122
PB Consultants Bureau
DT Journal
LA English
AB The luminescence was studied of 3-(2-R-thiazol-4-yl)coumarins (R = Me, CH2CN, Ar) and some isomeric 3-(4-R-thiazol-2-yl)coumarins (R = Ar) with substituents of different electronic types both in the coumarin and in the aryl moieties. Ests. were obtained of the rate consts. for primary photophys. processes: emission of fluorescence and nonradiative degradation of the electronic excitation energy. The matrix elements for the spin-orbit coupling operator, and based on these matrix elements the intersystem crossing rate consts., were calculated Deterioration of the fluorescent properties of the studied thiazolyl derivs. of coumarin when π-conjugated moieties are introduced into the thiazole ring is determined by the enhancement of the spin-orbit interaction in a system of levels of the π, π-type.
IT **209974-99-2 209975-00-8**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)
(luminescence and spin-orbit coupling in)
RN 209974-99-2 HCAPLUS
CN 2(1H)-Quinolinone, 3-(2-phenyl-4-thiazolyl)- (9CI) (CA INDEX NAME)



RN 209975-00-8 HCAPLUS
CN 2(1H)-Quinolinone, 6-methoxy-3-(2-phenyl-4-thiazolyl)- (9CI) (CA INDEX NAME)



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File

Asimov, M	1988	149	140	Chem Phys Lett	HCAPLUS
Asimov, M	1994			Inst Fiz Akad Nauk B	
Asimov, M	1991	70	384	Opt Spektrosk	HCAPLUS
Asimov, M	1992		44	Vestsi AN Belarusi	
Babich, E	1990		17	Teor Eksp Khim	HCAPLUS
Basharin, S	1990	52	48	Zh Prikl Spektrosk	
Griffits, J	1982	3	211	Dyes and Pigments	
Kovalenko, S	1995	76	189	Kazan Med Zh	
McGlynn, S	1972			Molecular Spectrosco	
Melhuish, W	1961	65	229	J Phys Chem	HCAPLUS
Minkin, V	1973	8	249	Int J Sulfur Chem	
Muldakhmetov, Z	1983			Optical and Magnetic	
Ponomarev, O	1989	8	1369	Khim Fiz	HCAPLUS
Ponomarev, O	1991	65	1846	Zh Fiz Khim	HCAPLUS
Sprague, J	1987	8	581	J Comp Chem	HCAPLUS
Ware, W	1973	77	2038	J Phys Chem	HCAPLUS
Ya, V	1997		1345	Khim Geterotsikl Soe	
Yu, F	1990	69	313	Opt Spektrosk	
Yu, F	1990	69	550	Opt Spektrosk	

L28 ANSWER 9 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1993:191726 HCAPLUS
DN 118:191726
TI Preparation oxazole and thiazole derivatives as active oxygen inhibitors
IN Chihiro, Masatoshi; Komatsu, Hajime; Tominaga, Michiaki; Yabuuchi, Youichi
PA Otsuka Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 560 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9209586	A1	19920611	1991WO-JP01659	19911129 <--
	W: AU, CA, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	CA---2074933	AA	19920531	1991CA-2074933	19911129 <--
	CA---2074933	C	20021203		
	AU---9189367	A1	19920625	1991AU-0089367	19911129 <--
	AU----656930	B2	19950223		
	CA---2547947	AA	19920625	1991CA-2547947	19911129 <--
	EP----513387	A1	19921119	1991EP-0920815	19911129 <--
	EP----513387	B1	20000301		
	R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	JP--05051318	A2	19930302	1991JP-0342495	19911129 <--
	EP----934937	A1	19990811	1999EP-0107493	19911129 <--
	EP----934937	B1	20020227		
	R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	ES---2144403	T3	20000616	1991ES-0920815	19911129 <--
	EP---1130017	A2	20010905	2001EP-0112988	19911129 <--
	EP---1130017	A3	20010919		
	EP---1130017	B1	20050615		
	R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	ES---2173683	T3	20021016	1999ES-0107493	19911129 <--
	ES---2245660	T3	20060116	2001ES-0112988	19911129 <--
	US---5643932	A	19970701	1995US-0444728	19950519 <--
	US---5677319	A	19971014	1995US-0482657	19950607 <--
	US---6080764	A	20000627	1997US-0826343	19970325 <--
	JP--10101562	A2	19980421	1997JP-0233370	19970813 <--
	JP---3182556	B2	20010703		
	HK---1003938	A1	20000721	1998HK-0103139	19980416 <--
	US-----37556	E	20020219	1999US-0245914	19990208 <--
PRAI	1990JP-0337727	A	19901130 <--		
	1991CA-2396738	A3	19911129 <--		
	1991EP-0920815	A3	19911129 <--		

1999EP-0107493	A3	19911129	<--
1991JP-0342495	A3	19911129	<--
1991WO-JP01659	A	19911129	<--
1992US-0916082	B1	19920729	<--
1995US-0444728	A3	19950519	<--
1995US-0482657	A3	19950607	<--

OS MARPAT 118:191726
GI



AB The title compds. [I; R1 = (substituted) Ph; R2 = H, halo, alkyl, Ph alkoxycarbonyl, alkylamino, etc.; R3 = Q (wherein R = OH, CO2H, alkyl, alkenyl; m = 0-2); X = S, O], useful in treating thrombosis, arteriosclerosis, peptic ulcers, etc., are prepared A suspension of 367 mg II and 430 mg 3,4-(MeO)2C6H3CSNH2 in EtOH was refluxed to give 160 mg thiazole salt III, which showed IC50 of 1 μM against superoxide formation. I were also effective in treating arrhythmia, ischemic renal disorders, and myocardial necrosis.

IT **145737-12-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as active oxygen inhibitor)

RN 145737-12-8 HCAPLUS

CN 2(1H)-Quinolinone, 3-[2-(3,4-dimethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



L28 ANSWER 10 OF 10 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 1991:143103 HCAPLUS
DN 114:143103
TI 2-oxo-3-cyanobenzo[h]quinoline. Part II. Some reactions on 3-methyl ketone derivative
AU Michael, J.; Nabih, I.; El-Zahar, M.
CS Lab. Med. Chem., Natl. Res. Cent., Cairo, Egypt
SO Egyptian Journal of Chemistry (1990), Volume Date 1988, 31(1), 117-24
CODEN: EGJCA3; ISSN: 0367-0422
DT Journal
LA English
OS CASREACT 114:143103

GI



AB Bromination of RCOMe (R = Q throughout) by Br2-AcOH gave 86% RCOCH2Br (I) which was treated with KSCN to give 50% RCOCH2SCN followed by intramol. cycloaddn. to give 47% thiazole II (R1 = OH). Addnl. obtained were II (R1 = NH2, Me) from I and H2NCSNH2 and MeCSNH2, resp. Oxidation of I by SeO2-EtOH and SeO2-dioxane gave 75 and 79% RCOCO2Et and RCOCHO, resp. which were cyclocondensed with o-H2NC6H4NH2 to give 53% quinoxaline III and 52% quinoxaline IV, resp. Addnl. obtained were 52-84% benzoquinolines V (X = O, R2 = Me2CH, Bu, Ph; X = S, R2 = Me, Ph) and 68% benzopyranoquinolinone VI.

IT **132894-68-9P 132894-69-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 132894-68-9 HCAPLUS

CN Benzo[h]quinolin-2(1H)-one, 3-(2-amino-4-thiazolyl)-5,6-dihydro-4-phenyl- (9CI) (CA INDEX NAME)



RN 132894-69-0 HCAPLUS

CN Benzo[h]quinolin-2(1H)-one, 5,6-dihydro-3-(2-methyl-4-thiazolyl)-4-phenyl- (9CI) (CA INDEX NAME)




```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 09:24:52 ON 15 AUG 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:24:52 ON 15 AUG 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs fhitstr hitrn l32 3-4

L32  ANSWER 3 OF 10  USPATFULL on STN
AN     2004:294735  USPATFULL
TI     Compounds and methods of uses
IN     Norman, Mark H., Thousand Oaks, CA, United States
       Wang, Hui-Ling, Thousand Oaks, CA, United States
       Rzasa, Robert, Ventura, CA, United States
       Zhong, Wenge, Thousand Oaks, CA, United States
       Nguyen, Thomas, Thousand Oaks, CA, United States
       Kaller, Matthew, Ventura, CA, United States
       Liu, Hu, Brooklyn, NY, United States
PA     Amgen, Inc., Thousand Oaks, CA, United States (U.S. corporation)
PI     US---6822097       B1   20041123
AI     2003US-0360226          20030206 (10)
PRAI   2002US-355313P      20020207 (60)                          <--
DT     Utility
FS     GRANTED
EXNAM  Primary Examiner: Seaman, D. Margaret
CLMN   Number of Claims: 44
ECL    Exemplary Claim: 1
DRWN   0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 15475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Selected compounds are effective for treatment of diseases, such as cell
       proliferation or apoptosis mediated diseases. The invention encompasses
       novel compounds, analogs, prodrugs and pharmaceutically acceptable
       derivatives thereof, pharmaceutical compositions and methods for
       prophylaxis and treatment of diseases and other maladies or conditions
       involving stroke, cancer and the like. The subject invention also
       relates to processes for making such compounds as well as to
       intermediates useful in such processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT  578017-64-8P
        (preparation of thiazolyl substituted quinolinones for treating cell
        proliferative disorders, neurol. disorders and apoptosis)
RN  578017-64-8  USPATFULL
CN  5-Quinolinecarboxylic acid, 1,2-dihydro-2-oxo-3-[2-(4-pyridinyl)-4-
      thiazolyl]-, methyl ester (9CI)  (CA INDEX NAME)
```



IT 578017-64-8P 578017-68-2P 578017-70-6P
578017-96-6P 578018-16-3P 578018-20-9P
578018-25-4P 578018-29-8P 578018-34-5P
578018-44-7P 578018-57-2P 578018-62-9P
578018-82-3P 578018-85-6P 578018-94-7P
(preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)

IT 209974-99-2P 578017-57-9P 578017-58-0P
578017-59-1P 578017-60-4P 578017-61-5P
578017-62-6P 578017-63-7P 578017-65-9P
578017-66-0P 578017-67-1P 578017-69-3P
578017-71-7P 578017-72-8P 578017-73-9P
578017-74-0P 578017-75-1P 578017-76-2P
578017-77-3P 578017-78-4P 578017-79-5P
578017-80-8P 578017-81-9P 578017-82-0P
578017-83-1P 578017-84-2P 578017-85-3P
578017-87-5P 578017-89-7P 578017-90-0P
578017-92-2P 578017-94-4P 578017-95-5P
578017-97-7P 578017-98-8P 578017-99-9P
578018-00-5P 578018-01-6P 578018-02-7P
578018-03-8P 578018-04-9P 578018-05-0P
578018-06-1P 578018-07-2P 578018-08-3P
578018-09-4P 578018-10-7P 578018-11-8P
578018-12-9P 578018-13-0P 578018-14-1P
578018-15-2P 578018-17-4P 578018-18-5P
578018-19-6P 578018-21-0P 578018-22-1P
578018-23-2P 578018-24-3P 578018-26-5P
578018-27-6P 578018-28-7P 578018-30-1P
578018-31-2P 578018-32-3P 578018-33-4P
578018-35-6P 578018-36-7P 578018-37-8P
578018-38-9P 578018-39-0P 578018-40-3P
578018-41-4P 578018-42-5P 578018-43-6P
578018-45-8P 578018-46-9P 578018-47-0P
578018-48-1P 578018-49-2P 578018-50-5P
578018-51-6P 578018-52-7P 578018-53-8P
578018-54-9P 578018-55-0P 578018-56-1P
578018-58-3P 578018-59-4P 578018-60-7P
578018-61-8P 578018-63-0P 578018-64-1P
578018-65-2P 578018-66-3P 578018-67-4P
578018-68-5P 578018-69-6P 578018-76-5P
578018-77-6P 578018-78-7P 578018-79-8P
578018-80-1P 578018-81-2P 578018-83-4P
578018-84-5P 578018-86-7P 578018-87-8P
578018-88-9P 578018-89-0P 578018-90-3P
578018-91-4P 578018-92-5P 578018-93-6P
578018-95-8P 578018-96-9P 578018-97-0P
578018-98-1P 578018-99-2P 578019-00-8P
578019-01-9P 578019-02-0P 578019-03-1P
578019-04-2P 578019-05-3P 578019-06-4P
578019-07-5P 578019-08-6P 578019-09-7P
578019-10-0P 578019-11-1P 578019-12-2P
578019-13-3P 578019-14-4P 578019-15-5P
578019-16-6P 578019-17-7P 578019-18-8P
578019-19-9P 578019-20-2P 578019-21-3P
578019-22-4P 578019-23-5P 578019-24-6P

578019-25-7P 578019-26-8P 578019-27-9P
578019-28-0P 578019-29-1P 578019-30-4P
578019-31-5P 578019-32-6P 578019-33-7P
578019-34-8P 578019-35-9P 578019-36-0P
578019-37-1P 578019-38-2P 578019-39-3P
578019-40-6P 578019-41-7P 578019-42-8P
578019-43-9P 578019-44-0P 578019-45-1P
578019-46-2P 578019-47-3P 578019-48-4P
578019-49-5P 578019-50-8P 578019-51-9P
578019-52-0P 578019-53-1P 578019-54-2P
578019-55-3P 578019-56-4P 578019-57-5P
578019-58-6P 578019-59-7P 578019-60-0P
578020-21-0P 578020-22-1P 578020-24-3P
578020-26-5P 578020-27-6P 578020-28-7P
(preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)

IT 578020-18-5 578020-20-9
(preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)

IT 578020-04-9P 578020-08-3P 578020-09-4P
578020-11-8P 578020-12-9P 578020-13-0P
578020-14-1P 578020-15-2P
(preparation of thiazolyl substituted quinolinones for treating cell proliferative disorders, neurol. disorders and apoptosis)

L32 ANSWER 4 OF 10 USPATFULL on STN
AN 2004:190788 USPATFULL
TI Pyrid-2-one derivatives and methods of use
IN Zhong, Wenge, Thousand Oaks, CA, UNITED STATES
Norman, Mark Henry, Thousand Oaks, CA, UNITED STATES
Kaller, Matthew, Ventura, CA, UNITED STATES
Nguyen, Thomas, Thousand Oaks, CA, UNITED STATES
Rzasa, Robert Michael, Ventura, CA, UNITED STATES
Tegley, Christopher, Thousand Oaks, CA, UNITED STATES
Wang, Hui-Ling, Thousand Oaks, CA, UNITED STATES
PI US2004147561 A1 20040729
AI 2003US-0736289 A1 20031212 (10)
PRAI 2002US-436787P 20021227 (60) <--
DT Utility
FS APPLICATION
LREP AMGEN INC., U.S. Patent Operations/JWB, Dept. 4300, M/S 27-4-A, One Amgen Center Drive, Thousand Oaks, CA, 91320-1799
CLMN Number of Claims: 39
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7376
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 727383-80-4P, 2-Methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid trifluoroacetate
(Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)
RN 727383-80-4 USPATFULL
CN 3-Pyridinecarboxylic acid, 1,6-dihydro-2-methyl-6-oxo-5-[2-(4-pyridinyl)-4-thiazolyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 727383-79-1
CMF C15 H11 N3 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **727383-80-4P**, 2-Methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid trifluoroacetate
(Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)

IT **727382-46-9P**, Ethyl 2-ethyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydropyridine 3-carboxylate **727382-58-3P**, Ethyl 2-isopropyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-61-8P**, Ethyl 2-isopropyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-78-7P 727383-04-2P**, Ethyl 5-[2-(2-chloro-4-pyridinyl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-27-9P**, Ethyl 5-[2-[2-(4-Methoxybenzylamino)pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-30-4P**, Ethyl 2-methyl-5-[2-(methylamino)-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-52-0P**, 2-(Isopropyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylic acid **727383-77-9P**, 1,1-Dimethylethyl 2-methyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-89-3P**, 5-Hydroxymethyl-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one **727384-52-3P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid (2-hydroxyethyl)amide **727384-54-5P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid (2-hydroxypropyl)amide **727384-61-4P**, 2-(2-Benzyloxyethyl)-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid ethyl ester **727384-65-8P**, 2-(2-Hydroxyethyl)-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid ethyl ester
(Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)

IT **727382-48-1P 727382-49-2P**, Ethyl 2-ethyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-50-5P**, Ethyl 2-ethyl-6-oxo-5-[2-(benzodioxol-5-yl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-51-6P**, Ethyl 6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-(trifluoromethyl)-1,6-dihydro-3-pyridinecarboxylate **727382-53-8P**, Ethyl 2-trifluoromethyl-6-oxo-5-[2-(3-chloro-4-

pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-55-0P**, Ethyl 6-oxo-5-[2-[(2-pyridylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-(trifluoromethyl)-1,6-dihydro-3-pyridinecarboxylate **727382-56-1P**, Ethyl 6-oxo-5-[2-[(2-thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-(trifluoromethyl)-1,6-dihydro-3-pyridinecarboxylate **727382-57-2P**, Ethyl 2-trifluoromethyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-60-7P**, Ethyl 2-isopropyl-6-oxo-5-[2-[(2-thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-62-9P**, Ethyl 2-propyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-65-2P**, Ethyl 2-propyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-66-3P**, Ethyl 2-propyl-6-oxo-5-[2-[(2-thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-67-4P**, Ethyl 6-oxo-2-[(phenylmethoxy)methyl]-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-71-0P**, Ethyl 6-oxo-2-[(phenylmethoxy)methyl]-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-72-1P** **727382-74-3P**, 3-[2-(Pyridin-4-yl)-1,3-thiazol-4-yl]-1,7,8-trihydro-5H-pyrano[4,3-b]pyridin-2-one **727382-76-5P** **727382-79-8P**, 3-[2-(Pyridin-4-yl)-1,3-thiazol-4-yl]-1,5,6,7,8-pentahydropyridino[3,2-c]pyridin-2-one dihydrochloride **727382-80-1P**, Ethyl 2-[[(4-methoxyphenyl)methoxy]methyl]-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-85-6P**, Ethyl 2-methyl-6-oxo-5-[2-[(2-thienylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-89-0P**, Ethyl 5-[2-[[[(4-fluorophenyl)methyl]sulfonyl]methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727382-90-3P**, Ethyl 2-methyl-6-oxo-5-[2-(2-thienyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-92-5P**, Ethyl 2-methyl-6-oxo-5-[2-(phenylthiomethyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-93-6P**, Ethyl 5-[2-(2-ethyl-4-pyridinyl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727382-94-7P**, Ethyl 2-methyl-6-oxo-5-[2-[[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-95-8P**, Ethyl 2-methyl-6-oxo-5-[2-(3-thienyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-96-9P**, Ethyl 5-[2-(2H-benzo[d]-1,3-dioxolan-5-yl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727382-97-0P**, Ethyl 2-methyl-6-oxo-5-(2-phenyl-1,3-thiazol-4-yl)-1,6-dihydro-3-pyridinecarboxylate **727382-98-1P**, Ethyl 2-methyl-6-oxo-5-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727382-99-2P**, Ethyl 5-[2-(2,6-dichlorophenyl)-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-00-8P**, Ethyl 2-methyl-5-[2-(2-methyl-1,3-thiazol-4-yl)-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-01-9P**, Ethyl 5-[2-[[(furan-2-ylmethyl)sulfonyl]methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-02-0P**, Ethyl 5-[2-[[(tert-butyl)sulfonyl]methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-03-1P**, Ethyl 2-methyl-6-oxo-5-[2-(3-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-06-4P**, Ethyl 2-methyl-6-oxo-5-[2-(4-methoxyphenyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-07-5P**, Ethyl 5-[2-(3,5-dichloropyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-08-6P**, Ethyl 5-[2-[(methylsulfonyl)methyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-09-7P**, Ethyl 5-[2-[3-[[(4-chlorophenyl)sulfonyl]methyl]-2-thienyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-10-0P**, Ethyl 2-methyl-6-oxo-5-[2-[2-(1-piperidinyl)-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate **727383-11-1P**, Ethyl 2-methyl-5-[2-[2-[(2-methylpropyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate **727383-12-2P**, Ethyl 2-methyl-6-oxo-5-[2-[2-[(3-pyridinylmethyl)amino]-4-pyridinyl]-1,3-

thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-13-3P, Ethyl 2-methyl-6-oxo-5-[2-[2-[(phenylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-14-4P, Ethyl 2-methyl-6-oxo-5-[2-[2-[2-oxo-3-(trifluoromethyl)-1(2H)-pyridinyl]ethyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-15-5P, Ethyl 5-[2-[2-[[2-(diethylamino)ethyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-16-6P, Ethyl 5-[2-[2-[(fur-2-ylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-17-7P, Ethyl 5-[2-[2-[[2-(thien-2-yl)ethyl]amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-18-8P, Ethyl 5-[2-[2-(4-fluorobenzylamino)pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-19-9P, Ethyl 5-[2-(2-butylaminopyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-20-2P, Ethyl 5-[2-[2-[(carbamoylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-21-3P, Ethyl 5-[2-[2-[2-(acetylamino)ethylamino]pyridin-4-yl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-22-4P, N-[2-[[4-[4-(6-Methyl-2-oxo-1,2-dihydropyridin-3-yl)-1,3-thiazol-2-yl]pyridin-2-yl]amino]ethyl]acetamide 727383-23-5P, N-(Cyclopropylmethyl)-5-[2-[2-[(cyclopropylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxamide hydrochloride 727383-24-6P, Ethyl 5-[2-[2-[(cyclopropylmethyl)amino]pyridin-4-yl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-25-7P, Ethyl 5-[2-[2-[(Cyclopentylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-26-8P, 5-[2-[2-[(4-Methoxybenzyl)amino]pyridin-4-yl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(4-methoxybenzyl)amide hydrochloride 727383-28-0P, Ethyl 2-methyl-6-oxo-5-[2-[2-(amino)-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-29-1P 727383-31-5P, Ethyl 2-methyl-5-[2-[methyl(phenylsulfonyl)amino]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-32-6P 727383-33-7P, Ethyl 2-methyl-5-[2-[methyl(phenylsulfonyl)amino]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride (1/2) 727383-34-8P, 5-[(Phenylmethyl)oxy]-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-35-9P, 6-(Methoxymethyl)-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-37-1P, 5-Phenoxy-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-38-2P, 5-Phenoxy-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone hydrochloride (1/3) 727383-39-3P, 6-Methyl-3-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-40-6P, Ethyl 2-(1-methylethyl)-5-[2-(2-methoxy-4-pyridinyl)-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-42-8P, Ethyl 2-methyl-5-[2-[2-(methoxy)-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-43-9P, Ethyl 2-methyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-44-0P, Ethyl 2-methyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-45-1P, Ethyl 2-methyl-6-oxo-5-[2-[(2-pyridylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-46-2P, Ethyl 2-methyl-5-[2-[1-methyl-1-(phenylsulfonyl)ethyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-47-3P, Ethyl 2-cyclopropyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-51-9P, Ethyl 2-cyclopropyl-6-oxo-5-[2-[(phenylsulfonyl)methyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-53-1P, 5-Bromo-6-methyl-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-56-4P, Ethyl 2-methyl-5-[2-[2-(methylamino)-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-58-6P, 5-Amino-6-ethyl-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone

727383-65-5P, N-[2-Ethyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]acetamide 727383-66-6P, 4-Dimethylamino-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-68-8P, 6-Methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-5,6,7,8-tetrahydro-1H-[1,6]naphthyridin-2-one 727383-69-9P, 2-Methyl-6-oxo-N-(2-pyridinylmethyl)-5-[2-[2-[[(2-pyridinyl)methyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxamide 727383-70-2P, 6-Methyl-3-[2-[2-[(2-pyridinylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-71-3P, Ethyl 2-methyl-6-oxo-5-[2-[2-[(2-pyridinylmethyl)amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-72-4P, Ethyl 2-methyl-6-oxo-5-[2-[2-[[2-(phenyloxy)ethyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-73-5P, 5-[2-[2-(Ethoxy)-4-pyridinyl]-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 727383-75-7P, Ethyl 5-[2-(2-dimethylaminopyridin-4-yl)-1,3-thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate 727383-76-8P, Ethyl 5-[2-(2-methylaminopyridin-4-yl)-1,3-thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydro-3-pyridinecarboxylate hydrochloride 727383-79-1P, 2-Methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 727383-81-5P, 6-Methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone 727383-82-6P, 2-(Pyrrolidin-1-yl)ethyl 2-methyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylate 727383-84-8P, 2-(Pyrrolidin-1-yl)ethyl 2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylate 727383-85-9P, 6-Ethyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-86-0P, 6-Isopropyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-87-1P, 3-(Diethylamino)propyl 2-ethyl-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-88-2P, 3-(Diethylamino)propyl 2-(1-methylethyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-91-7P, 5-[(3,6-Dihydro-2H-pyridin-1-yl)methyl]-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-94-0P , 6-Ethyl-5-[(piperidin-1-yl)methyl]-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one hydrochloride 727383-96-2P, 6-Ethyl-5-(4-methylpiperazin-1-ylmethyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one hydrochloride 727383-98-4P, 6-Ethyl-5-isobutylamino-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-01-2P, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridin-3-yl]isobutyramide 727384-03-4P , 6-Isopropyl-5-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-06-7P, 3-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-6-isopropyl-5-methyl-1H-pyridin-2-one 727384-08-9P, 6-Ethyl-5-propionyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-10-3P, 3-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-6-ethyl-5-propionyl-1H-pyridin-2-one 727384-11-4P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-dimethylaminoethyl ester 727384-13-6P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(pyrrolidin-1-yl)ethyl ester 727384-14-7P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(2-oxopyrrolidin-1-yl)ethyl ester 727384-15-8P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-diisopropylaminoethyl ester 727384-16-9P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-diethylaminoethyl ester 727384-17-0P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 1-methylpyrrolidin-3-yl ester 727384-18-1P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 1-ethylpyrrolidin-3-yl ester 727384-19-2P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 1-ethylpiperidin-3-yl ester 727384-20-5P, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-

yl]-1,6-dihydropyridine-3-carboxylic acid piperidin-4-ylmethyl ester **727384-22-7P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(1-methylpyrrolidin-2-yl)ethyl ester **727384-23-8P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 1-methylpiperidin-3-yl ester **727384-24-9P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-dimethylamino-1-methylethyl ester **727384-25-0P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-diethylamino-1-methylethyl ester **727384-26-1P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-[(benzyl)(methyl)amino]ethyl ester **727384-27-2P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 1-methylpiperidin-4-yl ester **727384-28-3P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(piperazin-1-yl)ethyl ester **727384-29-4P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(2-oxopyrrolidin-1-yl)propyl ester **727384-30-7P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid phenethyl ester **727384-32-9P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(thiophen-2-yl)ethyl ester **727384-33-0P**, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 2-diethylaminoethyl ester **727384-36-3P**, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 2-diethylamino-1-methylethyl ester **727384-37-4P**, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 2-diethylaminopropyl ester **727384-38-5P**, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 2-(1-methylpyrrolidin-2-yl)ethyl ester **727384-39-6P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(morpholin-4-yl)ethyl ester **727384-40-9P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid 2-(piperidin-1-yl)ethyl ester **727384-41-0P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid methyl ester **727384-42-1P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid methyl ester trifluoroacetate **727384-43-2P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid propyl ester **727384-44-3P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid propyl ester trifluoroacetate **727384-45-4P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid butyl ester **727384-46-5P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid butyl ester trifluoroacetate **727384-47-6P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid isobutyl ester **727384-48-7P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid isobutyl ester trifluoroacetate **727384-49-8P**

, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid sec-butyl ester **727384-50-1P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid sec-butyl ester trifluoroacetate **727384-55-6P**, 5-(4,5-Dihydrooxazol-2-yl)-6-isopropyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one **727384-56-7P**, 6-Isopropyl-5-(5-methyl-4,5-dihydrooxazol-2-yl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one **727384-57-8P**, 5-[[(2-Dimethylaminoethyl)(ethyl)amino]methyl]-6-ethyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one **727384-59-0P**, 5-[[(2-Diethylaminoethyl)(methyl)amino]methyl]-6-ethyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one **727384-66-9P**,

6-Oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-2-[2-(pyrrolidin-1-yl)ethyl]-1,6-dihydropyridine-3-carboxylic acid ethyl ester **727384-68-1P**, 2-Isopropyl-N-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxamide **727384-69-2P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid amide **727384-70-5P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid isobutylamide **727384-72-7P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid methylamide **727384-73-8P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridine-3-carboxylic acid (2-isopropylaminoethyl)amide **727384-74-9P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid dimethylamide **727384-75-0P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid N-(pyridin-4-ylmethyl)amide **727384-76-1P**, 2-Isopropyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridine-3-carboxylic acid N-(pyridin-2-ylmethyl)amide **727384-78-3P**, 5-(Furan-2-yl)-6-isopropyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one **727384-83-0P**, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]-2-methylaminoacetamide **727384-84-1P**, 2-Dimethylamino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]acetamide **727384-85-2P**, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]-3-(piperidin-1-yl)propionamide **727384-86-3P**, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]-3-methylbutyramide **727384-87-4P**, 2-Amino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]acetamide **727384-88-5P**, 2-tert-Butylamino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]acetamide **727384-89-6P**, (S)-2-Amino-N-[2-ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]-3-methylbutyramide **727384-90-9P**, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]-2-(piperidin-1-yl)acetamide **727384-92-1P**, N-[2-Ethyl-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]-4-(piperidin-1-yl)butyramide **727384-93-2P**, 5-(1,1-Dioxidoisothiazolidin-2-yl)-6-ethyl-3-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-2(1H)-pyridinone **727384-94-3P**, 6-Ethyl-5-(3-methylbutylamino)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one **727384-95-4P**, Ethyl 5-[2-[2-[(fur-2-ylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate **727384-96-5P**, Ethyl 5-[2-[2-[[2-(thien-2-yl)ethyl]amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate **727384-97-6P**, Ethyl 5-[2-(2-butylaminopyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate **727384-98-7P**, Ethyl 5-[2-[2-[(carbamoylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate **727384-99-8P**, Ethyl 5-[2-(2-acetylaminoethylamino)pyridin-4-yl-1,3-thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate **727385-00-4P**, 5-[2-[2-[(Cyclopropylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid N-(cyclopropylmethyl)amide **727385-02-6P**, Ethyl 5-[2-[2-[(cyclopropylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate **727385-03-7P**, Ethyl 5-[2-[2-[(Cyclopentylmethyl)amino]pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate **727385-04-8P**, 5-[2-[2-(4-Methoxybenzylamino)pyridin-4-yl]thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 4-methoxybenzylamide **727385-06-0P**, Ethyl 5-[2-(2-methylaminopyridin-4-yl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylate **727385-07-1P**, Ethyl 2-methyl-5-[2-[2-[[2-[(1-methylethyl)amino]ethyl]amino]-4-pyridinyl]-1,3-thiazol-4-yl]-6-oxo-1,6-dihydropyridine-3-carboxylate **727385-08-2P**, Ethyl 2-isopropyl-6-oxo-5-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate hydrobromide (3/5)
(Cdk2/Cdk5 inhibitor; preparation of quinazolines as Cdk2 and Cdk5 kinase

inhibitors for treatment of cell proliferation-related disorders)
IT 727383-61-1P, Ethyl 2-ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylate 727383-62-2P, 2-Ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydro-3-pyridinecarboxylic acid 727383-63-3P, [2-Ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(4-pyridinyl)-1,3-thiazol-4-yl]-1,6-dihydropyridin-3-yl]carbamic acid tert-butyl ester 727383-64-4P, 5-Amino-6-ethyl-1-(4-methoxybenzyl)-3-[2-(4-pyridyl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-90-6P, 5-[(Imidazol-1-yl)carbonyl]-6-methyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-92-8P, 6-Ethyl-5-hydroxymethyl-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-93-9P, 6-Ethyl-1-(4-methoxybenzyl)-5-[(piperidin-1-yl)methyl]-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727383-95-1P, 6-Ethyl-1-(4-methoxybenzyl)-5-[(4-methylpiperazin-1-yl)methyl]-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-00-1P, 6-Ethyl-5-isobutylamino-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-02-3P, N-[2-Ethyl-1-(4-methoxybenzyl)-6-oxo-5-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1,6-dihydro-pyridin-3-yl]isobutyramide 727384-12-5P, 5-[(Imidazol-1-yl)carbonyl]-6-isopropyl-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-21-6P 727384-34-1P, 5-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-2-isopropyl-6-oxo-1,6-dihydro-3-pyridinecarboxylic acid 727384-35-2P, 3-[2-(Benzenesulfonylmethyl)thiazol-4-yl]-5-[(imidazol-1-yl)carbonyl]-6-isopropyl-1H-pyridin-2-one 727384-58-9P, 5-[[(2-Dimethylaminoethyl)(ethyl)amino]methyl]-6-ethyl-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one 727384-60-3P, 5-[[(2-Diethylaminoethyl)(methyl)amino]methyl]-6-ethyl-1-(4-methoxybenzyl)-3-[2-(pyridin-4-yl)-1,3-thiazol-4-yl]-1H-pyridin-2-one
(intermediate; preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)
IT 727383-74-6, 5-[2-(2-Chloropyridin-4-yl)thiazol-4-yl]-2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid 727384-67-0
(preparation of quinazolines as Cdk2 and Cdk5 kinase inhibitors for treatment of cell proliferation-related disorders)

=> d bib abs hitstr l32 1-2 5-10

L32 ANSWER 1 OF 10 USPATFULL on STN
AN 2005:131933 USPATFULL
TI Imidazo[1,2-a]pyridine derivative
IN Takemura, Makoto, Edogawa-ku, JAPAN
Takahashi, Hisashi, Edogawa-ku, JAPAN
Kawakami, Katsuhiro, Edogawa-ku, JAPAN
Takeshita, Hiroshi, Edogawa-ku, JAPAN
Kimura, Youichi, Edogawa-ku, JAPAN
Watanabe, Jun, Edogawa-ku, JAPAN
Sugimoto, Yuichi, Edogawa-ku, JAPAN
Kitamura, Akihiro, Edogawa-ku, JAPAN
Nakajima, Ryohei, Edogawa-ku, JAPAN
Kanai, Kazuo, Edogawa-kun, JAPAN
Fujisawa, Tetsunori, Takaoka-shi, JAPAN
PI US2005113397 A1 20050526
AI 2003US-0502971 A1 20030130 (10)
2003WO-JP00912 20030130
PRAI 2002JP-0022767 20020131 <--
DT Utility
FS APPLICATION
LREP SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 9053
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound reprsented by the following formula (I), its salts or nsolvates thereof capable of specifically or selectively expressig an antifungal activity in a broad spectrum based on the novel mechanism thereof of 1,6-β-glucan synthesis inhibition, and an antifungal agent containing any of them. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **577776-44-4P 577776-48-8P 577776-51-3P 577777-06-1P**
(preparation of imidazo[1,2-a]pyridine derivs. as antifungal agents with specific or selective 1,6-β-glucan)
RN 577776-44-4 USPATFULL
CN Pyrido[1,2-a]benzimidazole-4-carbonitrile, 1,5-dihydro-3-methyl-2-(2-methyl-4-thiazolyl)-1-oxo- (9CI) (CA INDEX NAME)



RN 577776-48-8 USPATFULL
CN Pyrido[1,2-a]benzimidazole-4-carbonitrile, 2-(2-ethyl-4-thiazolyl)-1,5-dihydro-3-methyl-1-oxo- (9CI) (CA INDEX NAME)



RN 577776-51-3 USPATFULL
CN Pyrido[1,2-a]benzimidazole-4-carbonitrile, 1,5-dihydro-3-methyl-1-oxo-2-(2-phenyl-4-thiazolyl)- (9CI) (CA INDEX NAME)



RN 577777-06-1 USPATFULL
CN Dipyrido[1,2-a:2',3'-d]imidazole-9-carbonitrile, 1,6-dihydro-8-methyl-7-(2-methyl-4-thiazolyl)-6-oxo- (9CI) (CA INDEX NAME)



L32 ANSWER 2 OF 10 USPATFULL on STN
AN 2005:57357 USPATFULL
TI Quinolinone derivatives as inhibitors of c-fms kinase
IN Wall, Mark J., Harleysville, PA, UNITED STATES
Player, Mark R., Phoenixville, PA, UNITED STATES
Patch, Raymond Joseph, Yardley, PA, UNITED STATES
Meegalla, Sanath, Boothwyn, PA, UNITED STATES
Liu, Jian, Plainsboro, NJ, UNITED STATES
Illig, Carl R., Phoenixville, PA, UNITED STATES
Cheung, Wing, Plainsboro, NJ, UNITED STATES
Chen, Jinsheng, Exton, PA, UNITED STATES
Asgari, Davoud, Newtown, PA, UNITED STATES
PI US2005049274 A1 20050303
AI 2004US-0894940 A1 20040720 (10)
PRAI 2003US-488811P 20030722 (60)
DT Utility
FS APPLICATION
LREP PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3251
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is directed to compounds of Formulae I and II: ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.6, Y.sup.1, Y.sup.2, Y.sup.3, Y.sup.4 and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **835880-69-8P**
(preparation of quinolinones as inhibitors of c-fms kinase)
RN 835880-69-8 USPATFULL
CN 6-Quinolinecarbonitrile, 4-(4-ethylphenyl)-1,2-dihydro-3-(2-methyl-4-thiazolyl)-2-oxo- (9CI) (CA INDEX NAME)



L32 ANSWER 5 OF 10 USPATFULL on STN

AN 2004:129634 USPATFULL
TI Naphthyridine derivatives
IN Iwata, Masahiro, Tsukuba, JAPAN
Kawano, Noriyuki, Tsukuba, JAPAN
Takuwa, Tomofumi, Tsukuba, JAPAN
Shiraki, Ryota, Tsukuba, JAPAN
Kobayashi, Miki, Tsukuba, JAPAN
Takeuchi, Makoto, Tsukui, JAPAN
PA Yamanouchi Pharmaceutical Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)
PI US---6740662 B1 20040525
WO2001030779 20010503 <--
AI 2002US-0111077 20020419 (10) <--
2000WO-JP07433 20001024 <--
PRAI 1999JP-0302544 19991025 <--
DT Utility
FS GRANTED
EXNAM Primary Examiner: Dentz, Bernard
LREP Sughrue Mion, PLLC
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2015
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 2-Oxo-1,2-dihydro-1,8-naphthyridine derivatives characterized by bearing a specific substituent, --X--R.sup.6, at the 3-position and a cyclic substituent, R.sup.5, at the 4-position; or salts thereof. The derivatives and the salts are useful as drugs, particularly preventive or therapeutic agents for respiratory diseases related to PDE IV.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **337358-29-9P**
(preparation of naphthyridine derivs. as phosphodiesterase IV inhibitors)
RN 337358-29-9 USPATFULL
CN 1,8-Naphthyridin-2(1H)-one, 3-(2-amino-4-thiazolyl)-4-(3-chlorophenyl)-1-ethyl-7-methyl- (9CI) (CA INDEX NAME)



IT **337358-74-4P**
(preparation of naphthyridine derivs. as phosphodiesterase IV inhibitors)
RN 337358-74-4 USPATFULL
CN Acetamide, N-[4-[4-(3-chlorophenyl)-1-ethyl-1,2-dihydro-7-methyl-2-oxo-1,8-naphthyridin-3-yl]-2-thiazolyl]- (9CI) (CA INDEX NAME)



L32 ANSWER 6 OF 10 USPATFULL on STN
AN 2003:79334 USPATFULL
TI Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production
IN Priepke, Henning, Warthausen, GERMANY, FEDERAL REPUBLIC OF
Kauffmann-Hefner, Iris, Attenweiler, GERMANY, FEDERAL REPUBLIC OF
Hauel, Norbert, Schemmerhofen, GERMANY, FEDERAL REPUBLIC OF
Damm, Klaus, Biberach, GERMANY, FEDERAL REPUBLIC OF
Schnapp, Andreas, Biberach, GERMANY, FEDERAL REPUBLIC OF
PA Boehringer Ingelheim Pharma KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US2003055263 A1 20030320
AI 2002US-0192456 A1 20020710 (10) <--
PRAI DE 2001-10133665 20010711 <--
2001US-307449P 20010724 (60) <--
DT Utility
FS APPLICATION
LREP BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2028
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present application relates to the use of the carboxylic acid derivatives of general formula

R.sub.1--A--B--R.sub.2 (I)

wherein

R.sub.1, R.sub.2, A and B are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, which have an inhibitory effect on telomerase, processes for the preparation thereof, pharmaceutical compositions containing these compounds and the use thereof as well as the preparation thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **488816-08-6P**
(drug candidate; preparation of thiazols and related compds. as telomerase inhibitors)
RN 488816-08-6 USPATFULL
CN Benzoic acid, 2-[[[4-(1,2-dihydro-2-oxo-3-quinolinyl)-2-thiazolyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



L32 ANSWER 7 OF 10 USPATFULL on STN
AN 2002:33452 USPATFULL
TI Superoxide radical inhibitor
IN Chihiro, Masatoshi, Naruto, JAPAN
Komatsu, Hajime, Tokyo, JAPAN
Tominaga, Michiaki, Itano-Gun, JAPAN
Yabuuchi, Yoichi, Tokushima, JAPAN
PA Otsuka Pharmaceutical Co., Ltd., Tokyo, JAPAN (non-U.S. corporation)
PI US-----37556 E1 20020219 <--
US---5643932 19970701 (Original)
AI 1999US-0245914 19990208 (9) <--
1995US-0444728 19950519 (Original) <--
RLI Continuation of Ser. No. US 916082, now abandoned
PRAI 1990JP-0337727 19901130 <--
DT Reissue
FS GRANTED
EXNAM Primary Examiner: Gerstl, Robert
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 6449
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A superoxide radical inhibitor containing, as an effective ingredient, an azole derivative represented by the general formula (1), ##STR1##

[wherein R.sup.1 represents a phenyl group which may have 1-3 lower alkoxy groups as substituent(s) on the phenyl ring, a phenyl group having a lower alkylenedioxy group, or the like; R.sup.2 represents a hydrogen atom, a phenyl group, a halogen atom, a lower alkoxycarbonyl group, a lower alkyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, a dihydrocarbostyril group, or the like; R.sup.3 represents a group of the formula, ##STR2##

(R.sup.4B represents a hydroxyl group, a carboxy group, a lower alkenyl group or a lower alkyl group, m represents 0, 1 or 2); X represents a sulfur atom or an oxygen atom] or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **145737-12-8P**
(preparation of, as active oxygen inhibitor)
RN 145737-12-8 USPATFULL
CN 2(1H)-Quinolinone, 3-[2-(3,4-dimethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



L32 ANSWER 8 OF 10 USPATFULL on STN
AN 2000:80772 USPATFULL
TI Superoxide radical inhibitor
IN Chihiro, Masatoshi, Naruto, Japan
Komatsu, Hajime, Tokushima, Japan
Tominaga, Michiaki, Tokushima, Japan
Yabuuchi, Yoichi, Tokushima, Japan
PA Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US---6080764 20000627 <--
AI 1997US-0826343 19970325 (8) <--
RLI Division of Ser. No. 1995US-0482657, filed on 7 Jun 1995 which is a division of Ser. No. 1995US-0444728, filed on 19 May 1995 which is a continuation of Ser. No. US 916082
PRAI 1990JP-3377727 19901130 <--
DT Utility
FS Granted
EXNAM Primary Examiner: Gerstl, Robert
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7154
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A superoxide radical inhibitor containing, as an effective ingredient, an azole derivative represented by the general formula (1), ##STR1## [wherein R.sup.1 represents a phenyl group which may have 1-3 lower alkoxy groups as substituent(s) on the phenyl ring, a phenyl group having a lower alkylenedioxy group, or the like; R.sup.2 represents a hydrogen atom, a phenyl group, a halogen atom, a lower alkoxycarbonyl group, a lower alkyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, a dihydrocarbostyril group, or the like; R.sup.3 represents a group of the formula, ##STR2## (R.sup.4B represents a hydroxyl group, a carboxy group, a lower alkenyl group or a lower alkyl group. m represents 0, 1 or 2); X represents a sulfur atom or an oxygen atom] or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **145737-12-8P**
(preparation of, as active oxygen inhibitor)
RN 145737-12-8 USPATFULL
CN 2(1H)-Quinolinone, 3-[2-(3,4-dimethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



L32 ANSWER 9 OF 10 USPATFULL on STN
AN 97:94251 USPATFULL
TI Superoxide radical inhibitor
IN Chihiro, Masatoshi, Naruto, Japan
Komatsu, Hajime, Itano-gun, Japan
Tominaga, Michiaki, Itano-gun, Japan
Yabuuchi, Yoichi, Tokushima, Japan
PA Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US---5677319 19971014 <--
AI 1995US-0482657 19950607 (8) <--

RLI Division of Ser. No. 1995US-0444728, filed on 19 May 1995 which is a continuation of Ser. No. 1992US-0916082, filed on 29 Jul 1992, now abandoned
PRAI 1990JP-0337727 19901130 <--
DT Utility
FS Granted
EXNAM Primary Examiner: Gerstl, Robert
LREP Finnegan, Henderson, Farabow, Garrett & Dunner
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6751
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A superoxide radical inhibitor containing, as an effective ingredient, an azole derivative represented by the general formula (1), ##STR1## [wherein R.sup.1 represents a phenyl group which may have 1-3 lower alkoxy groups as substituent(s) on the phenyl ring, a phenyl group having a lower alkylenedioxy group, or the like; R.sup.2 represents a hydrogen atom, a phenyl group, a halogen atom, a lower alkoxycarbonyl group, a lower alkyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, a dihydrocarbostyril group, or the like; R.sup.3 represents a group of the formula, ##STR2## (R.sup.4B represents a hydroxyl group, a carboxy group, a lower alkenyl group or a lower alkyl group. m represents 0, 1 or 2); X represents a sulfur atom or an oxygen atom] or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **145737-12-8P**
(preparation of, as active oxygen inhibitor)
RN 145737-12-8 USPATFULL
CN 2(1H)-Quinolinone, 3-[2-(3,4-dimethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



L32 ANSWER 10 OF 10 USPATFULL on STN
AN 97:56698 USPATFULL
TI Superoxide radical inhibitor
IN Chihiro, Masatoshi, Naruto, Japan
Komatsu, Hajime, Itano-gun, Japan
Tominaga, Michiaki, Itano-gun, Japan
Yabuuchi, Yoichi, Tokushima, Japan
PA Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US---5643932 19970701 <--
AI 1995US-0444728 19950519 (8) <--
RLI Continuation of Ser. No. 1992US-0916082, filed on 29 Jul 1992, now abandoned
PRAI 1990JP-0337727 19901130 <--
DT Utility
FS Granted
EXNAM Primary Examiner: Gerstl, Robert
LREP Finnegan, Henderson, Farabow, Garrett & Dunner
CLMN Number of Claims: 11
ECL Exemplary Claim: 9
DRWN No Drawings
LN.CNT 6708

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A superoxide radical inhibitor containing, as an effective ingredient, an azole derivative represented by the general formula (1), ##STR1## [wherein R.sup.1 represents a phenyl group which may have 1-3 lower alkoxy groups as substituent(s) on the phenyl ring, a phenyl group having a lower alkylenedioxy group, or the like; R.sup.2 represents a hydrogen atom, a phenyl group, a halogen atom, a lower alkoxycarbonyl group, a lower alkyl group, an amino-lower alkyl group which may have a lower alkyl group as a substituent, a dihydrocarbostyril group, or the like; R.sup.3 represents a group of the formula, ##STR2## (R.sup.4B represents a hydroxyl group, a carboxy group, a lower alkenyl group or a lower alkyl group. m represents 0, 1 or 2); X represents a sulfur atom or an oxygen atom] or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **145737-12-8P**
(preparation of, as active oxygen inhibitor)

RN 145737-12-8 USPATFULL

CN 2(1H)-Quinolinone, 3-[2-(3,4-dimethoxyphenyl)-4-thiazolyl]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 08:52:57 ON 15 AUG 2006)

FILE 'HCAPLUS' ENTERED AT 08:59:25 ON 15 AUG 2006

L1 1 US2004147561/PN OR (US2003-736289 OR US2002-436787# OR US2006-3
E ZHONG W/AU
L2 302 E3-14
E ZHONG WEN/AU
L3 10 E3
E ZHONG WENGE/AU
L4 17 E3
E NORMAN M/AU
L5 39 E3,E10
E NORMAN MARK/AU
L6 85 E3,E7-8
E KALLER M/AU
L7 9 E4,E6-8
E NGUYEN T/AU
L8 1055 E3-60
E RZASA R/AU
L9 21 E4-7
E RZASA B/AU
L10 1 E3
E TEGLEY C/AU
L11 51 E4-7
E WANG H/AU
L12 1995 E3,E24
E WANG HUI/AU
L13 1715 E3,E52-54
E WANG HUILING/AU
L14 67 E2-3

```
                E HUI N/AU
                E HUIING N/AU
                E HUILING N/AU
                E WENGE N/AU

     FILE 'REGISTRY' ENTERED AT 09:07:36 ON 15 AUG 2006

     FILE 'HCAPLUS' ENTERED AT 09:07:37 ON 15 AUG 2006
L15             TRA L1 1- RN :      403 TERMS

     FILE 'REGISTRY' ENTERED AT 09:07:37 ON 15 AUG 2006
L16          403 SEA L15
L17          403 S L15
L18          283 S L17 AND NC5/ES
L19          211 L18 AND (NCSC2 OR NSCNC)/ES
L20              STR
L21              STR L20
L22           26 L21
L23          453 L21 FULL
                 SAV TEM L23 DAV289FO/A
L24          208 L23 AND L16

     FILE 'HCAPLUS' ENTERED AT 09:18:38 ON 15 AUG 2006
L25           14 L23
L26            2 L25 AND L1-14
L27           12 L25 NOT L26
L28           10 L27 AND (PY<=2002 OR AY<=2002 OR PRY<=2002)

     FILE 'HCAOLD' ENTERED AT 09:19:16 ON 15 AUG 2006
L29            0 L23

     FILE 'USPATFULL, USPAT2' ENTERED AT 09:19:24 ON 15 AUG 2006
L30           10 L23
L31            9 L30 AND (PY<=2002 OR AY<=2002 OR PRY<=2002)
L32           10 L30-31

=>
```